Blog
RSS FeedPosted by Michael Wonder on 16 Sep 2022
Evusheld long-acting antibody combination recommended for approval in the EU for the treatment of COVID-19
16 September 2022 - Recommendation based on TACKLE Phase 3 treatment data showing reduced risk of severe COVID-19 or death. ...
Posted by Michael Wonder on 16 Sep 2022
PHARMAC can't progress cystic fibrosis drug Trikafta - CF New Zealand
16 September 2022 - PHARMAC is not in a position to progress funding on the life-extending cystic fibrosis drug, Trikafta, ...
Posted by Michael Wonder on 09 Sep 2022
B.C. family grateful for expanded funding to cystic fibrosis drug, but questions why it took so long
7 September 2022 - B.C. is last Canadian jurisdiction to fund Trikafta for patients with cystic fibrosis age 6 to 11. ...
Posted by Michael Wonder on 02 Sep 2022
Vertex announces U.S. FDA approval for Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis ages 12 to <24 months
2 September 2022 - With this approval, approximately 300 children with two copies of the F508del mutation will have a ...
Posted by Michael Wonder on 02 Sep 2022
Azurity Pharmaceuticals announces FDA approval of Konvomep (omeprazole and sodium bicarbonate for oral suspension)
2 September 2022 - Azurity Pharmaceuticals announced today that the US FDA has approved Konvomep (omeprazole and sodium bicarbonate for oral ...
Posted by Michael Wonder on 31 Aug 2022
Amneal announces submission of new drug application to the US FDA for IPX203 for the treatment of Parkinson’s disease
31 August 2022 - IPX203 is a novel, extended-release oral formulation of carbidopa and levodopa that if approved, would offer patients ...
Posted by Michael Wonder on 30 Aug 2022
Evusheld long-acting antibody combination approved for prevention and treatment of COVID-19 in Japan
30 August 2022 - First global approval for Evusheld as a COVID-19 treatment. ...
Posted by Michael Wonder on 24 Aug 2022
Access criteria for new COVID-19 treatment announced
25 August 2022 - PHARMAC has today confirmed the access criteria for the first preventative medicine for COVID-19, tixagevimab and cilgavimab ...
Posted by Michael Wonder on 23 Aug 2022
European Medicines Agency commences review of oral fixed-dose combination of decitabine and cedazuridine for the treatment of adults with acute myeloid leukaemia
22 August 2022 - Otsuka and Astex Pharmaceuticals today announce that the EMA has accepted the marketing authorisation application for the ...
Posted by Michael Wonder on 20 Aug 2022
Axsome Therapeutics announces FDA approval of Auvelity, the first and only oral NMDA receptor antagonist for the treatment of major depressive disorder in adults
19 August 2022 - Auvelity is the first and only rapid-acting oral treatment approved with labelling of statistically significant improvement in ...
Posted by Michael Wonder on 18 Aug 2022
Chiesi’s Trimbow recommended for use within NHS Scotland
18 August 2022 - The SMC approval brings much needed boost to asthma sufferers across Scotland. ...
Posted by Michael Wonder on 17 Aug 2022
PHARMAC estimates Trikafta could give people with CF another 27 years
17 August 2022 - PHARMAC has today published the record of advice from the May PTAC meeting to again consider ...
Posted by Michael Wonder on 07 Aug 2022
Myovant Sciences and Pfizer receive U.S. FDA approval of Myfembree, a once daily treatment for the management of moderate to severe pain associated with endometriosis
5 August 2022 - Data from the Phase 3 SPIRIT program showed Myfembree reduced menstrual pain and non-menstrual pelvic pain in ...
Posted by Michael Wonder on 07 Jul 2022
Vertex announces letter of intent with the pan-Canadian Pharmaceutical Alliance for public reimbursement of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 and older
7 July 2022 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...
Posted by Michael Wonder on 04 Jul 2022
Accuretic users annoyed over contaminated blood pressure medication muddle
4 July 2022 - Confusion continues as Kiwis learn months after the rest of the world that widely used blood ...